WebApr 5, 2024 · Ruth O’Regan, MBBCh, BAO. Optimal patient selection and duration of therapy are the 2 biggest areas to tackle regarding CDK4/6 inhibition in the adjuvant setting of estrogen receptor (ER ... WebMar 17, 2024 · The PADMA trial is investigating palbociclib plus endocrine therapy compared to physician’s choice of chemotherapy with and without endocrine therapy. The primary endpoint of PADMA is time to treatment failure and, to date, 160 women with HER+ HER2-negative metastatic breast cancer have been enrolled.
Moving CDK4/6 Inhibition to HER2+ Breast Cancer - OncLive
WebNov 13, 2024 · The phase III PATINA trial is testing the value of adding palbociclib to trastuzumab (± pertuzumab) and endocrine therapy maintenance after induction therapy in the first-line setting. The phase II monarcHER trial compared abemaciclib and trastuzumab, with or without fulvestrant, to chemotherapy plus trastuzumab. The triplet combination … WebCOLLABORATION. Alliance Trials, LLC (AFT) offers clinical trial investigators, pharmaceutical partners and the Alliance for Clinical Trials in Oncology institutional member network collaborative opportunities to develop and conduct trials, in addition to NCI-funded initiatives. This expands access and trial design options. chennai homes senior living
Palbociclib and Letrozole in Advanced Breast Cancer
WebAFT-38/MBC-01/PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer Phase: Phase III Study Chair: O. Metzger WebJun 10, 2024 · It is Institute investigators who are leading a clinical trial of one such drug in almost 6,000 women around the world with a specific type of breast cancer. And it is Institute researchers who have shown in a group of highly influential studies over the past two years that the drugs may be even more powerful than originally suspected. WebThe aim of PATINA is to evaluate the efficacy and safety of the addition of palbociclib to anti-HER2 tx and ET maintenance after induction tx in the 1st line setting for HRþ/HER2þMBC. Trialdesign:The PATINA trial (AFT-38/NCT02947685) is a pivotal, open-label, inter-national, phase III study. The trial is open to patients (pts) with ... chennai homes posh